PMID- 34083302
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20231213
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 41
IP  - 6
DP  - 2021 Jun
TI  - Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line 
      Treatment in Metastatic Colorectal Cancer.
PG  - 3091-3097
LID - 10.21873/anticanres.15093 [doi]
AB  - BACKGROUND/AIM: The efficacy of folinic acid, fluorouracil, and irinotecan 
      (FOLFIRI) plus ramucirumab (F-RAM) or aflibercept (F-AFL) as a second-line 
      treatment in metastatic colorectal cancer (mCRC) is established. In this study, 
      the risks and benefits of F-RAM/AFL as a third-line treatment after first- and 
      second-line bevacizumab for mCRC were evaluated. PATIENTS AND METHODS: Overall 
      survival (OS) and adverse events (AEs) were compared between groups treated with 
      F-RAM/AFL (n=17) and trifluridine/tipiracil combination tablet (TAS-102) (n=26). 
      RESULTS: Median OS was longer in the third-line F-RAM/AFL group (379 days; 
      95%CI=157-458 days) than in the TAS-102 group (183 days; 95%CI=80-204 days) 
      (log-rank test, p=0.015). Discontinuation due to AEs was only observed in the 
      F-RAM/AFL group (3 cases). CONCLUSION: As a third-line treatment for mCRC, 
      F-RAM/AFL should be prioritized over TAS-102 in terms of efficacy; however, the 
      risk of AEs should be considered.
CI  - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kimura, Michio
AU  - Kimura M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan; 
      kimkim0305nao@yahoo.co.jp.
FAU - Usami, Eiseki
AU  - Usami E
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
FAU - Teramachi, Hitomi
AU  - Teramachi H
AD  - Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
RN  - IFL protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Camptothecin/administration & dosage/adverse effects/*analogs & derivatives
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Female
MH  - Fluorouracil/administration & dosage/adverse effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leucovorin/administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Receptors, Vascular Endothelial Growth Factor/*administration & dosage
MH  - Recombinant Fusion Proteins/*administration & dosage/adverse effects
MH  - Ramucirumab
OTO - NOTNLM
OT  - Ramucirumab
OT  - adverse event
OT  - aflibercept
OT  - bevacizumab
OT  - metastatic colorectal cancer
OT  - overall survival
OT  - third-line treatment
EDAT- 2021/06/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/06/04 06:05
PHST- 2021/04/08 00:00 [received]
PHST- 2021/04/19 00:00 [revised]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/06/04 06:05 [entrez]
PHST- 2021/06/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 41/6/3091 [pii]
AID - 10.21873/anticanres.15093 [doi]
PST - ppublish
SO  - Anticancer Res. 2021 Jun;41(6):3091-3097. doi: 10.21873/anticanres.15093.